الفهرس 
Introduction
Aim of the studyOnly 14 pages are availabe for public view
 |  | from | 108 |  |  |
| | | from | 108 | | |
Abstract
conclusion, this study shows that FDR gemcitabine given before radiotherapy is clinically effective as radiosensitizer for newly diagnosed GBM. Gemcitabine has more cost effectivness as regard financial cost in comparison to Temozolamide. Further investigation of chemo-radiotherapy is needed, especially when thet gemcitabine radiosensitizing effect can be achieved irrespective of the methylation status of the MGMT promoter (Metro et al, 2010).
It also showed that In vitro Addition of MK-2206 to gemcitabine significantly enhanced inhibition of cell proliferation and spheroid growth and inhibited the gemcitabine and RT mediated pAkt stimulation. The use of gemcitabine in combination with PI3kinase-Akt pathway inhibitors is a promising tool in GBM therapy and might be an alternative for patients resistant to temozolomide.